KalVista Pharmaceuticals, Inc. - KALV STOCK NEWS

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company, will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 11:00 a.m. ET. A live webcast will be available on their website, along with an audio archive accessible for 30 days post-event.

KalVista is focused on the development of oral, small molecule protease inhibitors for unmet medical needs, including sebetralstat, which is in the Phase 3 KONFIDENT clinical trial for HAE attacks. They are also advancing an oral Factor XIIa inhibitor program aimed at enhancing treatment options for HAE and other conditions.

KalVista Pharmaceuticals (KALV) reported significant operational progress, achieving over 50% enrollment in the pivotal phase 3 KONFIDENT trial for sebetralstat. The company completed a $58 million financing, ensuring funding into 2025, while publishing phase 2 trial results in The Lancet. Q3 financial results showed no revenue and a net loss of $21.3 million, an improvement from $22.5 million year-over-year. R&D expenses increased to $20.1 million, reflecting ongoing clinical trials. KalVista remains focused on addressing hereditary angioedema treatment needs and plans to utilize new funding for trials and general corporate purposes.

KalVista Pharmaceuticals presented five posters at the 2023 AAAAI Annual Meeting in San Antonio, Texas, showcasing key findings related to sebetralstat, an oral treatment for Hereditary Angioedema (HAE). The research indicates that orally disintegrating tablets display similar pharmacokinetics to existing film-coated tablets, which supports potential lifecycle extensions in the US and EU. Data also illustrate the treatment burden of injectable therapies, with an emphasis on the advantages of sebetralstat. Notably, Phase 2 trial results show that early treatment can significantly lower attack severity and cumulative symptom burden compared to placebo.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the acceptance of multiple abstracts for the 2023 Annual Scientific Meeting of the American Academy of Allergy, Asthma & Immunology in San Antonio, Texas, from February 24-27. Results from studies will be presented on February 26 from 9:45-10:45 a.m. CST. Key presentations include:

• Treatment with Sebetralstat for hereditary angioedema.
• Comparative bioavailability of Sebetralstat.
• Anxiety related to on-demand treatment for hereditary angioedema.
• Patient perspectives on early treatment for hereditary angioedema.
• Adverse drug reactions from parenteral treatments for hereditary angioedema.

KalVista focuses on oral protease inhibitors for unmet medical needs.

KalVista Pharmaceuticals has announced significant progress in its Phase 3 KONFIDENT clinical trial for sebetralstat, an oral therapy for hereditary angioedema (HAE) attacks. The trial has surpassed 50% enrollment of the 114 targeted patients, with expected topline data in the second half of 2023. The trial is active in 17 countries with more than 50 locations. Additionally, the FDA has provided guidance that no efficacy trials are required for a supplemental NDA for the oral disintegrating tablet formulation of sebetralstat. The company is also moving forward with regulatory pathways in Japan, targeting patient enrollment in both KONFIDENT and a follow-up study.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the publication of phase 2 trial results for its oral treatment, sebetralstat, in treating hereditary angioedema (HAE) attacks, featured in The Lancet. The trial included 68 patients, demonstrating that sebetralstat was well tolerated, offering rapid relief from attacks compared to placebo. Key findings included a significantly longer time to conventional treatment use and a faster onset of symptom relief. The promising results suggest sebetralstat could become the first oral, on-demand treatment for HAE patients. The company anticipates phase 3 KONFIDENT trial results in late 2023.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the expansion of its KONFIDENT trial for sebetralstat, an oral plasma kallikrein inhibitor, into Japan following positive phase 1 data indicating its efficacy and safety for short-term prophylaxis (STP) in Japanese adults. The KONFIDENT-S trial aims to evaluate the treatment's effectiveness. Additionally, a post hoc analysis from a phase 2 trial presented at the 60th Annual Scientific Session of the Western Society of Allergy, Asthma & Immunology demonstrated sebetralstat's consistent symptom relief across attack locations.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation at the virtual SVB Securities Global Biopharma Conference on February 16, 2023, at 8:40 a.m. ET. A live webcast of the presentation will be available on the company's website, with an audio archive for 30 days post-event. KalVista focuses on developing oral, small molecule protease inhibitors for conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME). The company is actively conducting the Phase 3 KONFIDENT trial for its oral therapy, sebetralstat, targeting HAE attacks and has a pipeline that includes a novel plasma kallikrein inhibitor for DME.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options to two new employees, allowing them to purchase a total of 14,000 shares of common stock at an exercise price of $7.64 each, equal to the stock's closing price on the grant date, February 1, 2023. The options will vest over a four-year period, with one-fourth vesting on the one-year anniversary and the remainder in monthly installments, contingent on continued employment. This move follows Nasdaq Listing Rule 5635(c)(4) and aligns with KalVista's commitment to attracting talent in the pharmaceutical sector, particularly in developing therapies for hereditary angioedema and diabetic macular edema.